Breaking News, Collaborations & Alliances

InterMune Earns Roche Milestone

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

InterMune, Inc. earned a $15 million development milestone under its collaboration with Roche for the hepatitis C virus (HCV) NS3 protease inhibitor compound ITMN-191 (R7227), currently in a Phase Ib combination trial with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin).     Under the terms of the 2006 collaboration agreement, Roche will take over primary responsibility for Phase II trials and for completing the global development and registration program for ITMN-191.          Nic...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters